[PRESS RELEASE] – CHICAGO, April 2, 2026 – Cresco Labs Inc., the industry leader in branded cannabis products with a portfolio of America’s most popular brands and the operator of Sunnyside dispensaries, announced that it has been conditionally awarded a Texas Compassionate Use Program license. It is a vertically integrated license, allowing Cresco Labs to cultivate, process and dispense medical cannabis.
"Texas patients deserve access to consistent, quality medicine, and we're excited to deliver it. Our track record in medical markets reflects our ability to build robust programs that put patients and communities first," Cresco Labs CEO Charlie Bachtell said. “Winning a license in Texas through a merit-based application points to Cresco Labs’s deep regulatory expertise and thoughtful approach to meaningful local engagement. Organic licensing enables capital-efficient market entry, and our cash generation and balance sheet give us the financial flexibility to invest and grow a scaled, long-term platform.”
This license advances Cresco Labs’s disciplined, state-by-state growth strategy and secures access to one of the largest patient populations in the United States. Texas is the nation’s second-most populous state, approaching 30 million people, and continues to see ongoing legislative efforts to improve patient access and broaden qualifying conditions.
